About the
NeLM
|
Help & Support
|
Site Feedback
|
Update Newsletter Subscription
Homepage
Login
|
Register
Search the NeLM
Medicines A-Z
Find key information about medicines by name (prototype)
Browse by Categories:
BNF Category
|
Medical Specialty
|
National Health Service
|
Medicines Information
Browse by NeLM area:
Evidence
|
Other Library Updates
|
News
|
Health In Focus
|
Medicines A-Z
|
Communities
|
Useful Links
|
Formularies
BNF Category
1: Gastro-intestinal system
2: Cardiovascular system
3: Respiratory system
4: Central nervous system
5: Infections
6: Endocrine system
7: Obstetrics, gynaecology, and urinary-tract disorders
8: Malignant disease and immunosuppression
9: Nutrition and blood
10: Musculoskeletal and joint diseases
11: Eye
12: Ear, nose, and oropharynx
13: Skin
14: Immunological products and vaccines
15: Anaesthesia
Appendix 7
Appendix 8 Wound management products and elasticated garments
Non-BNF miscellaneous
Emergency treatment of poisoning
8.1 Cytotoxic drugs
8.2 Drugs affecting the immune response
8.3 Sex hormones and hormone antagonists in malignant disease
8.1.1 Alkylating drugs
8.1.2 Anthracyclines and other cytotoxic antibiotics
8.1.3 Antimetabolites
8.1.4 Vinca alkaloids and etoposide
8.1.5 Other antineoplastic drugs
2300 library items
in 8.1 Cytotoxic drugs
Filter results by:
Date Published
2012 (191)
2011 (445)
2010 (444)
2009 (387)
2008 (271)
More
NeLM
Area
News
Other Library Updates
Health In Focus
Evidence
Medicines A-Z
Communities
Formularies
Results filtered by:
Category
8: Malignant disease and immunosuppression (
remove
)
,
8.1 Cytotoxic drugs (
remove
)
Sort by:
Least recent publication date
Most recent publication date
Title alphabetical A-Z
Title alphabetical Z-A
Source alphabetical A-Z
Source alphabetical Z-A
Display summary:
No
Yes
Results 1 - 10 of 2300
Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next
1.
Funding oncology clinical trials: are cooperative group trials sustainable?
Source:
Journal of Clinical Oncology
,
Date published:
15/05/2012
Category:
8.1 Cytotoxic drugs
|
Pharmaceutical Industry
NeLM
Area:
Evidence
>
Medicines Management
>
References
Abstract link
2.
SMC does not recommend ipilimumab (Yervoy®) for advanced melanoma
Source:
Scottish Medicines Consortium (SMC)
,
Date published:
15/05/2012
Category:
8.1.5 Other antineoplastic drugs
|
Cancer: skin
|
Drug reviews
|
Scottish Medicines Consortium
NeLM
Area:
Evidence
>
Drug Specific Reviews
Link to drug advice
3.
SMC accepts everolimus (Afinitor®) for use in the treatment of neuroendocrine tumours of pancreatic origin (pNET)
Source:
Scottish Medicines Consortium (SMC)
,
Date published:
15/05/2012
Category:
8.1.5 Other antineoplastic drugs
|
Drug reviews
|
Oncology
|
Scottish Medicines Consortium
NeLM
Area:
Evidence
>
Drug Specific Reviews
Link to drug advice
4.
SMC does not recommend bevacizumab (Avastin®) for first-line treatment of metastatic breast cancer
Source:
Scottish Medicines Consortium (SMC)
,
Date published:
15/05/2012
Category:
8.1.5 Other antineoplastic drugs
|
Cancer: breast
|
Drug reviews
|
Scottish Medicines Consortium
NeLM
Area:
Evidence
>
Drug Specific Reviews
Link to drug advice
5.
London Cancer New Drugs Group Rapid Review: Bortezomib as first line induction prior to melphalan and ASCT in untreated symptomatic multiple myeloma patients
Source:
London Cancer New Drugs Group
,
Date published:
15/05/2012
Category:
8.1.5 Other antineoplastic drugs
|
Cancer: other
|
Drug reviews
NeLM
Area:
Evidence
>
Drug Specific Reviews
LCNDG_Bortezomib_1st_line
6.
Interim analysis of phase III study of cetuximab for stage III colon cancer
Source:
PharmaLive
,
Date published:
14/05/2012
Category:
8.1.5 Other antineoplastic drugs
|
Cancer: gastroenterological
NeLM
Area:
News
Link
7.
Final NICE guidance does not recommend the use of cabazitaxel for the 2nd line treatment of hormone refractory, metastatic prostate cancer
Source:
NICE
,
Date published:
11/05/2012
Category:
8.1.5 Other antineoplastic drugs
|
Cancer: prostate
|
National Institute of Clinical Excellence (NICE)
NeLM
Area:
News
NICE guidance
Press release
8.
NICE draft guidance supports use of erlotinib for first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Source:
NICE
,
Date published:
10/05/2012
Category:
8.1.5 Other antineoplastic drugs
|
Cancer: lung
|
Clinical guidelines
|
National Institute of Clinical Excellence (NICE)
NeLM
Area:
News
Press release
Link to draft guidance
9.
Single agent maintenance therapy for advanced stage non-small cell lung cancer: meta-analysis
Source:
Lung Cancer
,
Date published:
10/05/2012
Category:
8.1 Cytotoxic drugs
|
8.2 Drugs affecting the immune response
|
Cancer: lung
NeLM
Area:
News
Abstract
10.
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: NOA-08 randomised, phase III trial
Source:
Lancet Oncology
,
Date published:
10/05/2012
Category:
8.1.5 Other antineoplastic drugs
|
Cancer: other
|
Care of Older People
NeLM
Area:
News
Abstract
Comment- full text access for subscribers only
Results 1 - 10 of 2300
Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next